Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 678-686

  Schellenberg, Devin ^a   Goodman, Karyn A ^b   Lee, Florence ^a   Chang, Stephanie ^a   Kuo, Timothy ^c   Ford, James M ^a   Fisher, George A ^a   Quon, Andrew ^a   Desser, Terry S ^a   Norton, Jeffrey ^a   Greco, Ralph ^a   Yang, George P ^a   Koong, Albert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Lake Norman Oncology   (United States)

Author keywords

Cyberknife; Gemcitabine; Image guided radiotherapy; Pancreatic cancer; Stereotactic body radiotherapy

Indexed keywords

CARBOHYDRATES; CHEMOTHERAPY; ELECTROTHERAPEUTICS; ORGANIC COMPOUNDS; RADIOTHERAPY; TOXICITY;

CARBOHYDRATE ANTIGEN; CHEMORADIOTHERAPY; CYBERKNIFE; DISEASE PROGRESSIONS; DOSE-LIMITING TOXICITY; DUODENAL ULCERS; FIRST CYCLE; FOUR CYCLES; FRACTIONATED RADIOTHERAPY; GASTROINTESTINAL TOXICITIES; GEMCITABINE; GROSS TUMOR VOLUME; IMAGE GUIDED RADIOTHERAPY; LATE EFFECTS; LOCAL CONTROL; MEDIAN SURVIVAL; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCER; PANCREATIC CANCERS; STEREOTACTIC BODY RADIOTHERAPY;

BIOTECHNOLOGY;

GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DUODENUM PERFORATION; DUODENUM STENOSIS; FEMALE; HUMAN; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; STOMACH ULCER; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; SURVIVORS;

EID: 52949109142     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.01.051     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189 (1999) 1-7
3. Ben-Josef E., Shields A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59 (2004) 454-459
4. Brade A., Brierley J., Oza A., et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. Int J Radiat Oncol Biol Phys 67 (2007) 1027-1036
5. Earle J.D., Foley J.F., Wieand H.S., et al. Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 28 (1994) 207-211
6. Hoyer M., Roed H., Sengelov L., et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76 (2005) 48-53
7. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57 (2003) 98-104
8. Okusaka T., Ito Y., Ueno H., et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91 (2004) 673-677
9. Poggi M.M., Kroog G.S., Russo A., et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54 (2002) 670-676
10. Rich T., Harris J., Abrams R., et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG 98-12. Am J Clin Oncol 27 (2004) 51-56
11. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53 (2002) 146-150
12. Willett C.G., Czito B.G., Bendell J.C., et al. Locally advanced pancreatic cancer. J Clin Oncol 23 (2005) 4538-4544
13. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
14. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48 (1981) 1705-1710
15. Cardenes H.R., Chiorean E.G., Dewitt J., et al. Locally advanced pancreatic cancer: Current therapeutic approach. Oncologist 11 (2006) 612-623
16. Okamoto A., Matsumoto G., Tsuruta K., et al. Intraoperative radiation therapy for pancreatic adenocarcinoma: The Komagome Hospital experience. Pancreas 28 (2004) 296-300
17. Willett C.G., Del Castillo C.F., Shih H.A., et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 241 (2005) 295-299
18. Crane C.H., Antolak J.A., Rosen II, et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30 (2001) 123-132
19. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
20. Kindler H.-L., Niedzwiecki D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). Presented at 2007 ASCO Annual Meeting. [Abstract]. J Clin Oncol 25 18S (2007) 4508
21. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006) 3946-3952
22. Philip P.A., Benedetti J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Presented at 2007 ASCO Annual Meeting. [Abstract]. J Clin Oncol 25 18S (2007) 4509
23. ECOG-4201. Phase III randomised study of gemcitabine with or without radiotherapy in patients with locally advanced, unresectable pancreatic cancer. Accessed at: http://www.rtog.org/studysummary/062007reports/ECOG4201.pdf
24. Yip D., Karapetis C., Strickland A., et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3 (2006) CD002093
25. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63 (2005) 320-323
26. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1017-1021
27. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. 2006. http://ctep.cancer.gov/forms/CTCAEv3.pdf
28. Murphy J.D., Adusumilli S., Griffith K.A., et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68 (2007) 801-808
29. de Lange S.M., van Groeningen C.J., Meijer O.W., et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38 (2002) 1212-1217
30. Blackstock A.W., Tepper J.E., Niedwiecki D., et al. Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34 (2003) 107-116
31. Epelbaum R., Rosenblatt E., Nasrallah S., et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81 (2002) 138-143
32. Magnino A., Gatti M., Massucco P., et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 68 (2005) 493-499
33. Symon Z. Tolerability of standard fractionation vs. hypofractionation in chemoradiotherapy of pancreatic cancer. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S284-S285
34. Wong A.A., Delclos M.E., Wolff R.A., et al. Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol 28 (2005) 227-233
35. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
36. Ferrone C.R., Finkelstein D.M., Thayer S.P., et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 2897-2902
37. Ziske C., Schlie C., Gorschluter M., et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89 (2003) 1413-1417